• +1-646-491-9876
    • +91-20-67278686

    Search

    Keloids-Pipeline Review H1 2017

    Keloids-Pipeline Review H1 2017

    • Report Code ID: RW0001834390
    • Category Pharmaceuticals
    • No. of Pages 46
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Keloids - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Keloids - Pipeline Review, H1 2017, provides an overview of the Keloids (Dermatology) pipeline landscape.

    Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroid, radiation, surgical removal and silicone gel or patches.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Keloids - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Keloids (Dermatology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Keloids (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

    Keloids (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Keloids (Dermatology) .
    - The pipeline guide reviews pipeline therapeutics for Keloids (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Keloids (Dermatology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Keloids (Dermatology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Keloids (Dermatology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Keloids (Dermatology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Keloids (Dermatology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Keloids - Overview
    Keloids - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Keloids - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Keloids - Companies Involved in Therapeutics Development
    FirstString Research Inc
    RXi Pharmaceuticals Corp
    Topadur Pharma AG
    Tumorend LLC
    viDA Therapeutics Inc
    Yuhan Corp
    Keloids - Drug Profiles
    CM-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Granexin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    koebnerisin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    psoriasin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RXI-109 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TOPN-44 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    V-2248 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VTI-3000 Series - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YH-siRNA1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Keloids - Dormant Projects
    Keloids - Discontinued Products
    Keloids - Product Development Milestones
    Featured News & Press Releases
    Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology
    Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study
    Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders
    Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
    Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision
    Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109
    Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Keloids, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Keloids - Pipeline by FirstString Research Inc, H1 2017
    Keloids - Pipeline by RXi Pharmaceuticals Corp, H1 2017
    Keloids - Pipeline by Topadur Pharma AG, H1 2017
    Keloids - Pipeline by Tumorend LLC, H1 2017
    Keloids - Pipeline by viDA Therapeutics Inc, H1 2017
    Keloids - Pipeline by Yuhan Corp, H1 2017
    Keloids - Dormant Projects, H1 2017
    Keloids - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Keloids, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    FirstString Research Inc
    RXi Pharmaceuticals Corp
    Topadur Pharma AG
    Tumorend LLC
    viDA Therapeutics Inc
    Yuhan Corp

    Request for Sample

    Report Url http://www.reportsweb.com//keloids-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//keloids-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//keloids-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments